FDA vs COFEPRIS: What Stem Cell Patients Need to Know (2026)

Why this comparison matters

Patients researching stem cell therapy run into the same confusion within the first hour. One source says stem cells are not FDA-approved. Another says Mexican clinics offer "FDA-quality" treatments. A third says everything is unregulated. None is fully accurate, and the gap between marketing and regulatory reality is where most mistakes happen.

Both the US and Mexico have functioning frameworks for cellular therapies. They differ in what counts as "approved", what physicians may do at the point of care, and how much oversight applies to expanded cell populations. This guide is balanced by design. The FDA exercises legitimate caution that has protected patients from real harm; COFEPRIS oversees a regulated environment in which cellular therapies are legally provided under specific conditions. The responsible question is not which country is "better" but which framework applies to the treatment you are considering.

The FDA's stance on stem cell therapy

The FDA regulates human cells, tissues, and cellular and tissue-based products under a framework known as HCT/P, governed by 21 CFR Part 1271. It divides cellular products into two pathways, and the difference between them is the single most important concept for a patient to understand.

The first pathway, Section 361 of the Public Health Service Act, applies to HCT/Ps that meet four criteria simultaneously: the product is minimally manipulated, intended for homologous use (the same basic function it had in the donor), not combined with a drug or device beyond minor exceptions, and either autologous, used in a first- or second-degree relative, or for reproductive use. Products meeting all four criteria can be marketed without premarket approval, though the establishment must register with the FDA and follow Good Tissue Practice. Conventional bone marrow transplants and certain tissue grafts are examples.

The second pathway, Section 351, applies to HCT/Ps that do not meet all the 361 criteria, including anything more than minimally manipulated, used for a non-homologous purpose, or culture-expanded. These are regulated as biological drugs, requiring an Investigational New Drug (IND) application for clinical trials and a Biologics License Application (BLA) to be marketed. BLA timelines typically span years, sometimes more than a decade.

In practice, most stem cell therapies offered globally, including expanded MSCs from umbilical cord tissue, fall into Section 351 territory in the US. They are investigational drugs, and providing them outside an approved clinical trial violates federal law. The FDA has issued warning letters and pursued enforcement against US clinics offering unapproved cellular products.

The FDA position is not that stem cells "do not work." It is that, with limited exceptions, expanded and allogeneic cellular products have not completed the pathway required for approved US sale. That caution is rooted in documented adverse events including infections, tumor formation, and product contamination linked to under-regulated clinics. It is a defensible posture.

COFEPRIS framework in Mexico

Mexico's federal health authority is the Comisión Federal para la Protección contra Riesgos Sanitarios (COFEPRIS). It operates under the General Health Law and Mexican Official Standards (NOMs), covering medicines, devices, biological products, clinical establishments, laboratories, and medical advertising. Our companion guide on COFEPRIS and regenerative medicine walks through the broader framework.

For cellular therapies, COFEPRIS regulates several layers at once. The clinical establishment must hold a sanitary notice (Aviso de Funcionamiento) registered federally. The processing laboratory must operate under documented standards covering air quality, microbiological controls, traceability, and release criteria. Allogeneic cellular products manufactured as therapies typically require sanitary registration under the categories for biological medicines. Medical advertising requires a separate advertising notice. The treating physician must hold a valid cédula profesional issued by the SEP. A clinic within this framework can be inspected by COFEPRIS at any time and is subject to pharmacovigilance obligations.

Mexico differs meaningfully from the US in how it treats culture-expanded autologous cells and certain allogeneic MSC products. Under the Mexican framework, these therapies can be provided in licensed clinical settings under defined conditions: documented informed consent, traceability of the cellular product, and adherence to applicable NOMs. They are not classified the way the FDA classifies them under Section 351, and that is a substantive regulatory difference rather than an absence of regulation. "Different from the FDA" does not mean "unregulated"; it means a different sovereign authority has drawn its lines elsewhere, within a framework the WHO recognizes as a regional reference authority for medicines and biological products.

Direct comparison

The table below summarizes structural differences between the two systems for the cellular therapies most patients ask about. It is a simplification by design.

| Dimension | FDA (United States) | COFEPRIS (Mexico) | |---|---|---| | Autologous, minimally manipulated cells (e.g., bone marrow concentrate) | Permitted under Section 361 if criteria met | Permitted in licensed clinics | | Autologous, culture-expanded MSCs | Investigational; requires IND/BLA pathway | Permitted in licensed clinics under defined conditions | | Allogeneic MSCs (e.g., umbilical cord, Wharton's jelly) | Investigational; not commercially approved as MSC therapy for joints | Available through licensed clinics using products with applicable sanitary registration | | Approval timeline for new biologic | Typically 7 to 15+ years through IND and BLA | Sanitary registration timelines vary; clinical use under medical practice does not require BLA-equivalent | | Primary oversight target | Manufacturer and product | Establishment, product, and advertising | | Out-of-pocket cost range (typical) | High, often within clinical trials only | Lower than US specialty biologics; varies by protocol | | Physician licensing | State medical boards | SEP cédula profesional, federal | | Adverse event reporting | FDA MedWatch | COFEPRIS pharmacovigilance system |

The "approval timeline" row is not a criticism; long timelines reflect the depth of evidence the FDA requires for a biologic to enter the US market. The "cost" row reflects manufacturing economics, IP, and the fact that US-commercial availability for MSC indications is largely limited to investigational settings.

What "approved" actually means

Much of the confusion in this field comes from the word "approved." Patients reasonably assume it means a regulator has reviewed safety and efficacy and signed off. That is correct for some uses and misleading for others.

When the FDA "approves" a biologic, the agency has reviewed a BLA containing clinical trial data, manufacturing details, and safety information, and concluded the product is safe and effective for a specific indication and population. There are FDA-approved cellular therapies, including certain CAR-T cancer therapies and a small number of stem cell products for blood and immune disorders. There are no FDA-approved MSC products for knee osteoarthritis, joint conditions broadly, or systemic regenerative use as of 2026.

When a clinic says a treatment is "approved" without naming a regulator and an indication, the statement is meaningless. The clinic might mean cells come from a registered tissue bank, the laboratory holds a sanitary license, the establishment holds a sanitary notice, or the physician is licensed. These are real categories, each independently verifiable, but none is the same as an FDA-approved drug. An honest clinic says so directly.

The most useful distinction is between informational and interventional regulation. Informational regulation covers labeling, manufacturing standards, and facility registration — ensuring what is provided is what is described, correctly prepared, and traceable. Interventional regulation requires premarket clinical evidence specific to an indication. Both the FDA and COFEPRIS perform informational regulation. The FDA's interventional regulation of cellular products is, by design, more restrictive than the equivalent in many jurisdictions including Mexico. A serious clinic in Mexico explains what is licensed, what is registered, what evidence supports the protocol, and what the limits of that evidence are. It does not claim FDA approval that does not exist.

How patients can verify COFEPRIS legitimacy

Verification is the most useful habit a patient can develop. COFEPRIS operates within a public regulatory system, and a clinic that resists the process is providing information of its own.

• Request the sanitary notice number in writing. Every clinic providing medical services in Mexico must file a notice. If a clinic will not provide this number, the inquiry should end there.
• Request the advertising notice number where applicable. Medical advertising is regulated separately, and the advertising notice framework constrains "miracle cure" language patients should treat as a red flag.
• Verify the physician's cédula profesional. Every licensed Mexican physician holds a cédula issued by the SEP, verifiable at cedulaprofesional.sep.gob.mx. Match it against credentials on a clinic's team page.
• Confirm the legal entity and address against the clinic's regulatory page; ours is at /en/legal/regulatorio.
• Ask where cellular products come from. A legitimate clinic names the processing laboratory, describes its sanitary authorizations, and explains the traceability chain.
• Ask which NOMs apply. A clinic within the system can name them without hesitation: NOM-004-SSA3-2012 for clinical records, plus applicable NOMs on informed consent, waste management, and biological products.

At Regeneris Therapy, our sanitary notice is 2323025036X00098 and our advertising notice is 2323022002A00053, both published in full on our regulatory information page.

Why many US patients seek stem cell therapy in Mexico

The pattern is well documented. A meaningful share of US patients who travel for stem cell therapy do so for three connected reasons: access to expanded and allogeneic cellular products not commercially available in the United States, cost structures substantially lower than US specialty care or trial-related expenses, and a willingness in Mexican clinical practice to deliver autologous expanded cells under physician oversight rather than restricting them to investigational pathways.

This is a description of the landscape, not a marketing claim. Patients with conditions for which there is no FDA-approved MSC therapy (knee osteoarthritis, certain autoimmune presentations, degenerative orthopedic conditions) often face a choice between waiting for US approval that may be years away, enrolling in a trial that may not be open to their case, or considering care in a jurisdiction where the treatment is legally available under a different regulatory model.

That choice carries trade-offs: the absence of the specific FDA evidentiary standard some patients want as baseline, the practical considerations of care abroad, and variability in clinic quality within Mexico itself. The trade-offs do not include "unregulated" treatment, provided the clinic genuinely operates within COFEPRIS, which is why verification matters more than any marketing claim. Our clinic safety guide for Mexico is a more detailed companion to this comparison.

Red flags in both jurisdictions

Bad actors exist in every country. The patterns differ; the pathology is similar: claims of certainty in a field where uncertainty is the responsible position, pricing that shifts at the door, refusal to provide documentation, and treatment plans that ignore basic clinical evaluation.

• Guaranteed outcomes or money-back promises for biologic therapy. No responsible provider offers either.
• "Approved" claims without an agency and indication attached. Ask which regulator approved what for whom.
• Pricing quoted only after a deposit, or significantly different on arrival than by email.
• Reluctance to provide regulatory documentation (FDA registration where applicable, COFEPRIS notice numbers in Mexico).
• Marketing that frames stem cells as a cure for unrelated conditions, from cancer to autism. Both agencies have taken action against this pattern.
• Compressed timelines that skip diagnostic workup, imaging, and informed consent.
• Anonymous "doctors" or named physicians whose licensing cannot be verified in a public registry.

A clinic worth considering, in either country, welcomes scrutiny and produces documentation without friction.

How Regeneris Therapy complies with COFEPRIS

Our compliance posture is documented and verifiable:

• Sanitary notice: 2323025036X00098, on file with COFEPRIS for our clinical operation in Cancun, Quintana Roo.
• Advertising notice: 2323022002A00053, governing the public communication of our medical services.
• Responsable Sanitario: named and credentialed, with verifiable cédula in the SEP public registry. Team credentials on our team page.
• Standards followed: NOM-004-SSA3-2012 for clinical records, plus applicable NOMs for waste management, informed consent, and biological products under the General Health Law.
• Cellular product sourcing: documented, traceable, and prepared under controlled laboratory conditions with signed release criteria before any administration.
• Pharmacovigilance: integrated into the clinical workflow with a defined channel for reporting adverse events.

Our full regulatory information page details each component with underlying documentation. To review our approach against a specific case, schedule a regenerative consultation; we walk through eligibility, evidence, and limits before any recommendation.

FAQ

Is stem cell therapy FDA approved in the United States? A small number of stem cell products are FDA approved, primarily hematopoietic stem cells for blood and immune disorders. For most regenerative indications in the consumer market, including knee osteoarthritis and general regenerative use, there is no FDA-approved MSC product as of 2026. Treatments offered in the US for these indications are typically investigational under an IND, autologous and minimally manipulated under Section 361, or, in some cases, offered outside the regulatory framework, which has been the subject of FDA enforcement.

Is stem cell therapy legal in Mexico? Yes, when provided in a COFEPRIS-licensed clinic, by a physician with a valid cédula, using cellular products that meet applicable Mexican requirements, with documented informed consent. The framework is real and verifiable.

Are stem cell treatments in Mexico safer than in the United States? Safety depends on the specific clinic, product, and protocol, not on the country. A licensed COFEPRIS clinic is no more or less safe in the abstract than a US clinic operating within its framework. The questions that determine safety are the same in both places.

Why are stem cell treatments cheaper in Mexico? Lower labor and facility costs, a regulatory framework that allows certain cellular therapies in clinical practice rather than only in investigational settings, and the absence of US-specific pricing pressures from insurers and the litigation environment. Lower cost does not, by itself, indicate lower quality.

Should I be worried about the FDA's position on stem cells? Take it seriously. Its caution is rooted in real harm from under-regulated products, and its evidentiary standard is high for good reason. At the same time, the position is a US regulatory framework, not a global verdict on the science. Many of the same MSC products under FDA review in trials are provided clinically elsewhere under different regimes.

How do I verify a Mexican clinic's COFEPRIS status? Ask for the sanitary and advertising notice numbers in writing, confirm the legal entity and address against the clinic's regulatory page, verify the physician's cédula in the SEP registry, and ask which NOMs the clinic operates under. Our companion COFEPRIS guide covers each step in detail.

Closing thoughts

The FDA and COFEPRIS are both real regulators applying real frameworks to a complex, evolving field. Neither replaces due diligence on a specific clinic. If you are considering stem cell therapy and want to make sense of where US and Mexican frameworks differ, our stem cell information hub is a structured starting point. The questions worth asking are concrete: what is approved, what is licensed, where does the product come from, who is the physician, what is the evidence, what are the risks. A clinic that takes those questions seriously, in either country, is worth your time.